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The detection, treatment and control of arterial hypertension have substantially contributed to the impressive decline of age-adjusted cardiovascular morbidity and mortality in Europe and in the United States in the past half century. Hypertension is the leading factor contributing to racial disparities in potential life-years lost. 1 The HELIUS study is a prospective cohort study on health in the urban multi-ethnic population of Amsterdam in The Netherlands. The current report is restricted to a cross-sectional analysis of data collected at baseline in 2011-2015. 2 Participants were aged 18-70 years and belonged to six different ethnic groups, which were men and women of African Surinamese origin, South-Asian Surinamese origin, Turkish origin, Moroccan origin, Ghanaian origin and Dutch origin. 2 The authors observed large ethnic differences in hypertension prevalence from young adulthood onwards, with African-origin populations showing the highest prevalence rates compared with the Dutch reference population. Differences in body mass index and waist:-hip ratio contributed importantly to the higher hypertension prevalence rate among ethnic minority groups, especially among Turks and Moroccans. However, a whole series of lifestyle, socio-economic and psychosocial variables could not fully explain the observed higher prevalence rates in African and South-Asian origin populations. An important aspect of the current study, which is only briefly mentioned in the Methods section, is that ethnic differences in hypertension prevalence were significantly modified by sex (p < 0.001). This is also striking at a glance when one compares odds ratios and 95% confidence intervals of odds ratios for both sexes in Table 2 in the study by Van Laer et al. 2 All models are inherently limited by residual confounding, unmeasured confounding, overadjustment bias or unnecessary adjustment. Nevertheless, it is reasonable to conclude that at least part of the ethnic/racial differences in hypertension prevalence can be attributed to genetic and gene-environmental underpinnings. This effect-modification may be sex-dependent. Finally, we do not know whether the effect of hypertension on organ damage and on clinically meaningful events is modified by race/ethnicity.
The topic of the impact of race/ethnicity on hypertension and on hypertension-induced organ damage is only briefly discussed in the 2018 ESC/ESH Guidelines for the management of arterial hypertension. 3 On the other hand, this topic has been investigated for several decades in the USA and has been mainly focused on differences between African-Americans and White Americans. The age-adjusted prevalence of hypertension from the National Health and Nutrition Examination Survey was 39.1% among AfricanAmericans, 28.5% among European Americans and 27.8% among Mexican Americans. 4 In a crosssectional analysis of adults without established cardiovascular disease aged 45 to 85 years recruited from six United States communities within the Multi-Ethnic Study of Atherosclerosis, African-American race/ ethnicity was associated with more than two-fold higher odds compared with Whites in all logistic regression models. 5 The Chinese racial/ethnic group was not associated with presence of hypertension in a model adjusted for age and sex but was after addition of demographic factors including body mass index and continued to be associated after further adjustment for education, income and financial strain. In contrast, Hispanic race/ethnicity was associated with presence of hypertension in the age-and sex-adjusted model but this association disappeared after further adjustments. compared with White. Increased risk for hypertension and higher prevalence for treated but uncontrolled hypertension in African-Americans has a profound effect on life expectancy. Stroke mortality risks are two-fold higher and end-stage renal disease is five times more common for African-Americans compared with Whites. 6 Low renin physiology, which is associated with a salt-sensitive phenotype whereby excess effective circulating volume is the mechanism of hypertension, is the most recognized biological profile associated with hypertension in subjects of African ethnicity. 7 Salt sensitivity in African-Americans is more prevalent than in Caucasians.
Prospective follow-up in the HELIUS study may provide insights into differences in incidence rates of major adverse cardiovascular outcomes in various ethnic groups. The population attributable fraction, the proportion of all cases in the population that can be attributed to the exposure (in this case hypertension), is an important public health outcome and depends on the prevalence of the risk factor and the strength of its association (relative risk, hazard ratio) with major adverse cardiovascular outcomes or total mortality. The population attributable fraction in the Charleston Heart Study in the United States for hypertension and 30-year mortality among White men was 23.8% compared with 45.2% among Black men and 18.3% for White women compared with 39.5% for Black women. 8 A substantial percentage of patients with hypertension do not achieve adequate control of blood pressure. African-Americans demonstrate poorer blood pressure control compared with Caucasians. 6 Racial differences in hypertension control in the United States cannot be attributed to differences in awareness and treatment patterns of hypertension. 6, 9 However, race/ethnicity may modify the response to non-pharmacological and pharmacological therapy for hypertension. The Dietary Approaches to Stop Hypertension (DASH) diet resulted in greater blood pressure reduction for African-Americans than Caucasians. 10 Calcium channel blockers and diuretics may result in greater blood pressure reduction in African-Americans whereas angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are not as effective in African-Americans compared with Caucasians. 5, 6 However, race-based therapy for hypertension, in other words whether race should be used as a branchpoint in the treatment algorithm, remains controversial. 11 Supportive evidence for race-based therapy is generally based on data of The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. 12 In this trial, 35% of the 33,357 participants, aged 55 years or older with hypertension and at least one other coronary heart disease risk factor, were Black. The primary outcome, fatal or non-fatal coronary heart disease, occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (six-year rate, 11.5%), the relative risks were 0.98 (95% confidence interval (CI), 0.90-1.07) for amlodipine (six-year rate, 11.3%) and 0.99 (95% CI, 0.91-1.08) for lisinopril (six-year rate, 11.4%). Differences were observed for several secondary endpoints. The lisinopril group had a 15% higher risk for stroke compared with chlorthalidone. However, incident stroke rates were virtually identical for lisinopril and chlorthalidone in non-Black subjects but were 40% higher in Black participants taking lisinopril. Race-based therapy should not be based on a subgroup analysis of a secondary outcome in a coronary heart disease trial. Moreover, angiotensin-converting enzyme inhibitors were more effective than b-blockers or dihydropyridine calcium channel blockers in slowing decline of glomerular filtration rate in the African-American Study of Kidney Disease and Hypertension, which recruited African-Americans with hypertensive nephrosclerosis. 13 Approximately 30% of participants in the Systolic Blood Pressure Intervention Trial, which compared the benefit of treatment of systolic blood pressure towards a target of less than 120 mmHg with treatment towards a target of less than 140 mmHg, were Black. 14 The treatment effect was similar in Blacks and nonBlacks. 14 There are many other reasons why it is far from evident to consider race/ethnicity as a branch-point in treatment algorithms. Race and ethnicity may be difficult to define and classify. Many different ethnic groups can be distinguished in, for example, China. Ethnic differences in blood pressure have been observed in the Chinese middle-aged population. 15 Heterogeneity in one race/ethnic group should be considered. Although low renin physiology is more prevalent in Blacks, no assumptions about low renin physiology can be made in an individual patient. Furthermore, clinical trials with hard clinical end points are the foundation for treatment and not pathophysiological concepts or genetic variants. This point raises also questions with regard to validity of the concept of precision medicine, specifically the assumption that individual genomic and epigenomic determinants will enable personalization of appropriate preventive and therapeutic interventions.
Taken together, the striking ethnic differences in hypertension prevalence in this report of the HELIUS study are important from a public health perspective and open a new dimension of hypertension research in Europe. However, race/ethnicity is unlikely to constitute a major factor in the clinical management of an individual patient with hypertension.
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